Evaluation of Muscle Mass from Chest CT versus Body Mass Index in Determining Severity and Outcomes in Non-Cystic Fibrosis Bronchiectasis - Scorecard - MDSpire
Advertisement
Evaluation of Muscle Mass from Chest CT versus Body Mass Index in Determining Severity and Outcomes in Non-Cystic Fibrosis Bronchiectasis
Clinical Scorecard: Evaluation of Muscle Mass from Chest CT versus Body Mass Index in Determining Severity and Outcomes in Non-Cystic Fibrosis Bronchiectasis
At a Glance
Category
Detail
Condition
Non-Cystic Fibrosis Bronchiectasis
Key Mechanisms
Destructive airways, increased sputum production, nutritional status impacting muscle mass and airway clearance.
Target Population
Patients diagnosed with bronchiectasis (ICD: J47).
Care Setting
Tertiary-care center.
Key Highlights
BMI is a significant predictor of disease severity in bronchiectasis.
L1 muscle index (L1MI) is proposed as a substitute for assessing muscle mass in bronchiectasis.
Nutritional status is critical for preventing muscle wasting and supporting airway clearance.
Guideline-Based Recommendations
Diagnosis
Use chest CT for diagnosing and assessing bronchiectasis severity.
Evaluate muscle mass using L1MI from chest CT.
Management
Incorporate nutritional assessments alongside traditional interventions.
Monitoring & Follow-up
Regularly assess exacerbation frequency and PPM colonization.
Risks
Low BMI is a significant risk factor for mortality in bronchiectasis.
Patient & Prescribing Data
Patients with bronchiectasis and associated comorbidities.
Continuous treatment with inhaled corticosteroids and macrolides may be beneficial.
Clinical Best Practices
Utilize comprehensive body composition analysis for better nutritional assessment.
Monitor muscle mass to improve management strategies in bronchiectasis.
